Femi Oluboyede

Femi Oluboyede has over nine years of work experience in the biopharmaceutical and healthcare industries. In 2021, they joined Revolo Biotherapeutics as VP of CMC and Sr Director of CMC, where they are responsible for leading CMC activities, manufacturing, overseeing CDMOs/CMOs, and delivering investigational drugs to support clinical trials. In 2020, they were Director of CMC at Stealth Bio. In 2019, they were Director and Associate Director of CMC at Cerecor Inc. In 2018, they were Upstream Development at MedImmune/AZ. In 2017, they were Senior Manager of CMC at Sucampo Pharmaceuticals, Inc. and CMC Manager at Vtesse, Inc. In 2014, they were a Strategy Consultant at Affinity Networks, Inc., where they conducted industry analysis within the Tele-healh/telemedicine industry and competitor analysis of firms offering tele-medicine products. In 2015, they were Senior Manager at Novavax. In 2014, they were an Independent Consultant at Inova Health System, where they initiated an ideation exercise to map-out the different aspects of personalized medicine implementation and carried out market research studies. In 2012, they were a Senior Consultant at IBM.

Femi Oluboyede completed a Master of Business Administration (MBA) from the University of Maryland - Robert H. Smith School of Business between 2010 and 2012, majoring in Entrepreneurship, Finance, Marketing, and Strategy. Femi also completed a MEng from the University of Surrey between 1995 and 2000, majoring in Chemical & Bioprocess Engineering.